BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Neximmune's AIM Immunotherapy Technology Enables Novel Adoptive Immunotherapy Approach For The Treatment Of Cancer


2/25/2014 10:19:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GAITHERSBURG, Maryland, February 25, 2014—NexImmune, an immunotherapy company developing products for the treatment of cancer, today announced a new scientific publication by NexImmune co-founder Dr. Jonathan Schneck and colleagues that provides an important advance in the use of its proprietary Artificial Immune (AIM?) Technology for cellular therapy of cancer. The study, published this week in ACS Nano, demonstrated the use of nanoparticle artificial Antigen Presenting Cells (aAPC), a key component of the AIM technology, with applied magnetic fields to activate and expand naive, normally poorly responsive T cell populations. Significantly, activated cells were highly effective for treating cancer in a mouse model system.

Activating naive T cells has been a key, but elusive goal of immunotherapy as these cells are more effective than differentiated T cell subtypes for treating cancer. Once activated, naive T cells have a higher proliferative capacity and a greater ability to generate strong, long-term T cell responses important for immunotherapy. Thus, this study describes a novel approach whereby AIM aAPC can potentially be coupled to magnetic-field-enhanced activation of T cells to increase the yield and activity of antigen-specific T cells expanded from naive precursors, thereby improving cellular therapy for cancer.

CEO Kenneth Carter commented: “The publication in ACS Nano represents an important advance in the therapeutic potential of the AIM aAPC technology in adoptive cellular therapy involving direct ex-vivo stimulation of patient immune cells. T cells activated by aAPC in a magnetic field inhibited growth of B16 melanoma in mice with significantly improved host survival, thereby demonstrating the clinical relevance of the AIM technology for adoptive immunotherapy.”

The AIM aAPC platform is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is guided by a synthetic particle engineered to activate and orchestrate a targeted immune response. Central to the AIM technology are aAPC that bypass many of the bottlenecks related to both established and emerging immunotherapies. AIM aAPC have potential uses as both ex vivo adoptive immunotherapies and as injectable off-the-shelf medicines. NexImmune, Inc. holds an exclusive worldwide license to the AIM aAPC technology from Johns Hopkins University.

About NexImmune

NexImmune is an early stage biopharmaceutical company developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIM?) nanotechnology. This nanotechnology platform is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is guided by a synthetic particle (artificial Antigen Presenting Cells, aAPC) that has been engineered to activate and orchestrate a targeted immune response. In pre-clinical studies, aAPC have been shown to have potential utility for treating cancer, infectious diseases and autoimmune diseases and can also be used for the development of diagnostic products. NexImmune is using the AIM technology to develop a pipeline of products to treat cancer. For more information visit: www.neximmune.com

Citation: Karlo Perica, et al., “Magnetic-field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity in vivo,” ACS Nano (2014).

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

Neximmune
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES